agenda

Amsterdam, 5 - 6 March 2025

Schedule

Create your personal agenda –check the favourite icon

Mar 58:00
Conference pass

Registration & Networking Meetings

Keynotes

Registration & Networking Meetings

Mar 58:55
Conference pass

Chair's Remarks

Keynotes

Chair's Remarks

Annette Powers, Senior Vice President, Global Market Access, Bristol Myers Squibb
Mar 59:00
Conference pass

Keynote presentation

Keynotes

Keynote presentation

Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson
Mar 59:20
Conference pass

Transforming market access through D.A.T.A. (Digital, AI, Technology & Analytics)

Keynotes
Mar 59:40
Conference pass

Industry commitments and collaborations to health system goals

Keynotes
Mar 510:00
Conference pass

Keynote Sponsor Presentation - Lifescience Dynamics

Keynotes

Session Reserved for LIfescience Dynamics

Mar 510:20
Conference pass

Trends and opportunities in achieving health equity from the Access to Medicine Index

Keynotes
Mar 510:40
Conference pass

Morning Break

Keynotes

Morning Break in Exhibition Hall

Mar 511:00
Conference pass

Morning Break & Poster Sessions

Keynotes

Poster sessions in exhibition hall

Mar 511:40
Conference pass

Chair's Remarks

Real World Evidence & Data, G102
Shuvayu Sen, Vice President, Head of Oncology, Center of Observational & Real-World Evidence, Merck & Co., Inc.
Mar 511:40
Conference pass

Chair's Remarks

Market Access, Auditorium
Reg Waldeck, Vice President, Oncology Market Access Strategy Leader, Bayer
Mar 511:40
Conference pass

Chair's Remarks

Pricing, Exhibition Hall
Nadine Sprangers, Vice President, Head of Global Oncology Value, Access and Pricing, Daiichi Sankyo
Mar 511:40
Conference pass

Chair's Remarks

Pre-Launch Success, G103
Gina Ewy, VP, Hansa Biopharma
Mar 511:40
Conference pass
Mar 511:40
Conference pass

Chair's Remarks

Rare Diseases, G105
Toon Digneffe, Head Public Affairs & Public Policy, Takeda
Mar 511:40
Conference pass

Chair's Remarks

Digital Transformation, G106
Katja Berg, Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU, AstraZeneca
Mar 511:40
Conference pass

Chair's Remarks

HTA, Exhibition Hall
Marlene Gyldmark, EU HTA lead, BeiGene
Mar 511:40
Conference pass

Chair's Remarks

Health Economics & Outcomes Research, G107
Riad Dirani, Vice President, Global Health Economics, Value and Outcomes, Teva Pharmaceuticals
Mar 511:45
Conference pass

Evidence generation in support of health equity

Real World Evidence & Data, G102
Kinga Borsos, Vice President, Head of US HEOR, Boehringer Ingelheim
Mar 511:45
Conference pass

Evaluating value of medicines through carbon footprint avoidance in the patient treatment pathway

Market Access, Auditorium
Sally Chung, Vice President, Value & Access International Operations & Excellence, Ipsen
Mar 511:45
Conference pass
Mar 511:45
Conference pass

Optimising long term launch commercial success with indication sequencing

Pre-Launch Success, G103
Mar 511:45
Conference pass

Reimbursement and pricing impacts - Israel perspective

Reimbursement, G104
Tomer Benzaken, Director, Head of Commercial Operations & Trade, Astellas
Mar 511:45
Conference pass

International access needs for orphan drugs: improving evidence and pricing strategies

Rare Diseases, G105
Ning Lu, Director, International Market Access and Pricing, Blueprint Medicines
Mar 511:45
Conference pass

Generative AI applications in market access and HEOR

Digital Transformation, G106
Bill Malcolm, Executive Director, Global HEOR Economic & Predictive Modelling, BMS
Mar 511:45
Conference pass

SUSTAIN-HTA innovative methodologies: advancing national and European HTA practice

HTA, Exhibition Hall
Mar 511:45
Conference pass

Improving gender disparities: advancing global health equity

Health Economics & Outcomes Research, G107
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Mar 512:05
Conference pass

The real world isn’t static, so don’t let your RWE be: harness the power of dynamic evidence

Real World Evidence & Data, G102
Mar 512:05
Conference pass

Securing launch success in Europe. The role of data and the JCA.

Market Access, Auditorium

Session reserved for sponsor

Pamela Vo, Vice President, HEOR, Value & Evidence, Eversana
Mar 512:05
Conference pass

Sponsor presentation

Pricing, Exhibition Hall

Session reserved for sponsor

Mar 512:05
Conference pass

How to leverage AI to optimise your brand for launch

Pre-Launch Success, G103

Session reserved for sponsor

Thomas Gilboy, Product Owner, Access Infinity
Mar 512:05
Conference pass

Sponsor presentation

Reimbursement, G104

Session reserved for sponsor

Mar 512:05
Conference pass

Sponsor presentation

Rare Diseases, G105

Session reserved for sponsor

Mar 512:05
Conference pass

Session Reserved for Stratence Partners

Digital Transformation, G106

Session reserved for sponsor

Mar 512:05
Conference pass

Session Reserved for Remap

HTA, Exhibition Hall

Session reserved for sponsor

Mar 512:05
Conference pass

Session Reserved for Initiate

Health Economics & Outcomes Research, G107

Session reserved for sponsor

Mar 512:25
Conference pass

RWE studies within registries: feasible or not?

Real World Evidence & Data, G102
Helene Chevrou-Severac, Senior Director, RWE & Outcomes Centre of Excellence Head, Alexion – AstraZeneca Rare Disease
Mar 512:25
Conference pass

Novel medicines platform: what does this mean for EU access policy?

Market Access, Auditorium
Matt Slabbert, Vice President, Global Head of Public Affairs, Astellas
Mar 512:25
Conference pass

Challenges of international reference pricing

Pricing, Exhibition Hall
Walmon Leal, Head of Global Pricing, Viatris
Mar 512:25
Conference pass

Early development plans: determining scenarios for value and outcomes in Europe

Pre-Launch Success, G103
Steven Flostrand, Executive Director, Value, Access & Pricing, Incyte Corp.
Mar 512:25
Conference pass

Advancing precision oncology across Europe: challenges for funding and reimbursement

Reimbursement, G104
Matthijs Van Meerveld, Associate Vice President, Global Head of Access Policy & Patient Advocacy, Oncology, Menarini Stemline
Mar 512:25
Conference pass

Expectations for collaborations between patient groups and industry in appraisal processes

Rare Diseases, G105
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Mar 512:25
Conference pass

FDA perspectives for AI in market access

Digital Transformation, G106
Carl Asche, Executive Director, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy
Mar 512:25
Conference pass

The psychology of HTA submissions: understanding payer decision making and the quality of submissions

HTA, Exhibition Hall
Timothy Mann, Director, Market Access, Jazz Pharma
Mar 512:25
Conference pass

Improving HTA disparities for Middle East and North Africa

Health Economics & Outcomes Research, G107
Mar 512:45
Conference pass

From aduhelm to leqembi: lessons in evidence-based pricing

Real World Evidence & Data, G102
Adam Weston, Executive Director, US and Global Pricing and Market Access Strategy, Genesis Research Group
Mar 512:45
Conference pass

Session Reserved for Decisive Consulting

Market Access, Auditorium

Session reserved for sponsor

Mar 512:45
Conference pass

Global price transparency: the what, how, and what now?

Pricing, Exhibition Hall

Session reserved for sponsor

Alex Grosvenor, Senior Vice President, Managing Director of Strategic Consulting, Precision AQ
David Carr, Senior Director, Strategic Consulting, Precision AQ
Mar 512:45
Conference pass

Session Reserved for Stratenym

Pre-Launch Success, G103

Session reserved for sponsor

Mar 512:45
Conference pass

Sponsor presentation

Reimbursement, G104

Session reserved for sponsor

Mar 512:45
Conference pass

How would orphan designated products under conditional marketing authorisation (EMA) perform along key EU HTA JCA assessment requirements?

Rare Diseases, G105
Susanne Michel, Head of HTA Methods and Evidence Planning, Clinigen
Florian Csintalan, Senior Consultant Market Access Strategy, Clinigen Group
Mar 512:45
Conference pass

AI agents incoming: is this your new price negotiator?

Digital Transformation, G106

Session reserved for sponsor

Mar 512:45
Conference pass

Session Reserved for Visible Analytics

HTA, Exhibition Hall

Session reserved for sponsor

Mar 512:45
Conference pass

Sponsor presentation

Health Economics & Outcomes Research, G107

Session reserved for sponsor

Hidde Nab, Associate Director, Innovation & Strategy, Asc Academics
Mar 513:05
Conference pass

Lunch

Keynotes

Lunch in Exhibition Hall

Mar 514:30
Conference pass

01 Real World Evidence & Data Panel – Advancing evidence generation using artificial intelligence

Real World Evidence & Data, G102
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Marco Penske, Head, Market Access & Healthcare Affairs, Germany, Boehringer Ingelheim
Cristina Valencia, Associate Director, Real World Evidence, Takeda
Enkeleida Nikai, Vice President, Head of Global Real-World Evidence, GenMed, Sanofi
Mar 514:30
Conference pass

01 Real World Evidence & Data Panel – Advancing evidence generation using artificial intelligence

Real World Evidence & Data, G102
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Rachel Studer, Global Evidence Executive Director, Oncology & Immunology, Novartis
Mar 514:30
Conference pass

02 Market Access Panel – Anticipated impacts of the EU HTA on market access

Market Access, Auditorium
Patrick Hopkinson, Independent HTA Expert
Marie Sanderson, Head of Value and Access Europe, Novartis
Sandeep Kiri, Global Head, Health Economic Evidence, UCB
Moderator: Marjan Willaert, Policy Advisor, Market Access, pharma.be
Jurgen Huismans, Director, HTA Strategy & Policy, MSD Innovation & Development GmbH
Mar 514:30
Conference pass

03 Pricing Panel - Reserved by Inbeeo

Pricing, Exhibition Hall

Session reserved by Inbeeo

Mar 514:30
Conference pass

04 Market Access Panel – Challenges and opportunities for access to innovation in LMICs

Pre-Launch Success, G103
Diana Sinkevich, Head of Access, EU & International, Global Rare Diseases, Chiesi
Mathieu Gilbert, Chief Operating Officer, Adocia
Pauline L'Hénaff, Head of Industry Engagement, Access to Medicine Foundation
Moderator: Jorge Arellano, Vice President, Head of Intercontinental Markets, Market Access, Pricing, & Value Demonstration, Bristol Myers Squibb
Mar 514:30
Conference pass

05 Reimbursement Panel – The UK subscription model for antimicrobials: what’s next internationally?

Reimbursement, G104
Warren Cowell, Director, Market Access UK, Shionogi Ltd
Grace Jennings, Senior Director, Outcomes Research, ICHOM
Moderator: Martina Garau, Director, Office of Health Economics
Mar 514:30
Conference pass

06 Rare Diseases Panel – Breaking down barriers for rare disease access: stakeholder perspectives

Rare Diseases, G105
Stefano Losi, Market Access Lead, Europe & Emerging Markets, Chiesi Group
Moderator: Sandrine Ruiz, Senior Director, Market Access, Pricing & HEOR, Immunocore Ltd
Eirini Palaka, Vice President, Global Value & Access for Rare Diseases, IPSEN
Fabian Schmidt, Global Head of Market Access, HEOR and Policy, Recordati Rare Diseases
Mar 514:30
Conference pass

07 Digital Transformation Panel – Patient-sourced data to accelerate digital transformation

Digital Transformation, G106
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Michela Pantaleoni, Chief Market Access Officer, Napo Therapeutics
Dawn Ireland, President, CDH International
Ramiro Gilardino, Associate Professor of Public Health, Buenos Aires School of Public Health
Moderator: Sania Chouman, Global Head of Access Innovation, Takeda
Mar 514:30
Conference pass

08 HTA Panel – Challenges for the implementation of the EU HTA

HTA, Exhibition Hall
Eelko Den Breejen, Sr. Director. Global Access Strategy & Pricing Oncology Team Lead. Portfolio & Market Engagement, Pfizer
Judith Fernandez, Deputy Director, HTA Department, French Authority for Health (HAS)
Moderator: Josep M Guiu, Director, Pharmacy and Medicines Area, Consortium of health and social care of Catalonia
Mar 514:30
Conference pass

09 Health Economics & Outcomes Research Panel – Optimizing AI in an evolving regulatory and HTA landscape

Health Economics & Outcomes Research, G107

Session reserved for sponsor

Jackie Vanderpuye-Orgle, Vice President, Global Head of Advanced Analytics, Parexel
Sangeeta Budhia, Vice President, Global Head of Pricing & Market Access, Parexel
Sugandh Sharma, Executive Director, HEOR: Evidence Evaluation, Parexel International
Dalia Dawoud, Associate Director, Research, NICE
Silvy Mardiguian, Senior Director, Head of HEOR, Europe & New Markets, BeiGene
Mar 515:30
Conference pass

Chair's Remarks

Real World Evidence & Data, G102
Mar 515:30
Conference pass

Chair's Remarks

Market Access, Auditorium
Don Creighton, Executive Director, Market Access Pipeline and Readiness Lead, Regeneron
Mar 515:30
Conference pass

Chair's Remarks

Pricing, Exhibition Hall
Luca Luigi Polastri, Global Value and Access Head, Nephrology Franchise, Kyowa Kirin
Mar 515:30
Conference pass

Chair's Remarks

Pre-Launch Success, G103
Mar 515:30
Conference pass

Chair's Remarks

Reimbursement, G104
Jean Louis Roux, Global Public Affairs and Communications, Ferring
Mar 515:30
Conference pass

Chair's Remarks

Rare Diseases, G105
Tomaso Piaggio, Head of Southern Cluster, International Market Access, Alnylam Pharmaceuticals
Mar 515:30
Conference pass

Chair's Remarks

Digital Transformation, G106
Adam Kundzewicz, Head of Market Access and Healthcare Affairs, Boehringer Ingelheim
Mar 515:30
Conference pass

Chair's Remarks

HTA, Exhibition Hall
Marnix Artz, Head, Patient Access, Pricing & Governmental Affairs, Merck Group
Mar 515:30
Conference pass

Chair's Remarks

Health Economics & Outcomes Research, G107

Chair's Remarks

Maurice Driessen, Senior Director, Head of Inline Brands, GHEVO, Teva Pharmaceuticals
Mar 515:35
Conference pass

Speaker presentation

Real World Evidence & Data, G102

Speaker presentation

Mar 515:35
Conference pass

Leading an innovative culture in access teams

Market Access, Auditorium
Iroda Jurabekova, Global Director, Oncology Pricing and Market Access, Boehringer Ingelheim
Mar 515:35
Conference pass

Developing fair pricing to increase rare disease access in emerging countries

Pricing, Exhibition Hall
Malik Ait-Yahia, Director, Head of Market Access, Pricing and Governmental Affairs, Biogen
Mar 515:35
Conference pass

Scaling innovation: how startups approach market access

Pre-Launch Success, G103
Hannah Kurth, Founder and Managing Director, Pulse Edge
Stephanie Juniat, Director, Commercial and Access Strategy, Cyted
Mar 515:35
Conference pass

Leveraging current reimbursement pathways to enable more equitable access for antibiotics

Reimbursement, G104
Jennifer Quinn, Head of Global Value and Access, Debiopharm International
Mar 515:35
Conference pass

Enabling earlier access for rare diseases: evaluating evidence for orphan drugs and payer challenges

Rare Diseases, G105
Eunice Alvazzi, Head of Global Value & Access, Hematology, Nephrology & Neurology,, Alexion – AstraZeneca Rare Disease
Mar 515:35
Conference pass

AI in the service of digital transformation

Digital Transformation, G106
Angela (Angie) Kehagia, Deputy Director, Senior HTA, KiTEC King's Technology Evaluation Centre
Mar 515:35
Conference pass

How have HTA agencies evolved their methods over time? The importance of understanding HTA reforms

HTA, Exhibition Hall
Martina Garau, Director, Office of Health Economics
Mar 515:35
Conference pass

Advancements in ctDNA: challenges in accepting global evidence requirements for payers

Health Economics & Outcomes Research, G107
Okke Bosgra, Director, International Market Access, Natera
Mar 515:55
Conference pass

Sponsor presentation

Real World Evidence & Data, G102

Reserved for sponsor

Mar 515:55
Conference pass

Session reserved for Access Infinity

Market Access, Auditorium

Reserved for Access Infinity

Mar 515:55
Conference pass

Session Reserved for RxData

Pricing, Exhibition Hall

Reserved for RxData

Mar 515:55
Conference pass

Session reserved for PDCI

Pre-Launch Success, G103

Reserved for PDCI

Mar 515:55
Conference pass

Portfolio access strategies - the why, the when, the how?

Reimbursement, G104
Smita Sealey, Principal, ZS
Mar 515:55
Conference pass

Session Reserved for Pharma Business Partners

Rare Diseases, G105

Reserved for Pharma Business Partners

Mar 515:55
Conference pass

Session Reserved for IQVIA

Digital Transformation, G106

Reserved for IQVIA

Mar 515:55
Conference pass

Eyes wide open: how is health equity data really impacting HTA outcomes?

HTA, Exhibition Hall
Mary Fletcher-Louis, Managing Director & Head of Value Center of Excellence, Trinity Life Sciences
Andreia Ribeiro, Associate Principal of Value, Access and Pricing, Trinity Life Sciences
Mar 515:55
Conference pass

Sponsor presentation

HTA, Exhibition Hall

Reserved for sponsor

Mar 515:55
Conference pass

Sponsor presentation

Health Economics & Outcomes Research, G107

Reserved for sponsor

Mar 516:15
Conference pass

RWE to support patient access: inequity of access across Denmark

Real World Evidence & Data, G102
Trine Pilgaard, Director, Head of Market Access, Denmark and Iceland, Pfizer
Mar 516:15
Conference pass

Augmenting patient access through technology: democratising digital tools for market access

Market Access, Auditorium
Vijay Reddy, Chief Commercial Officer, Avinya Biotech
Mar 516:15
Conference pass

Pricing challenges and changing mindsets for high cost therapies

Pricing, Exhibition Hall
Lara Pippo, Head of Market Access & Government Affairs, Italy, CSL Behring
Mar 516:15
Conference pass

Subnational reimbursement strategies for successful launches

Pre-Launch Success, G103
Olga Diachenko, Director Market Access, EMENA, Accord Healthcare
Mar 516:15
Conference pass

Advancing precision oncology across Europe: challenges for funding and reimbursement

Reimbursement, G104
Matthijs Van Meerveld, Associate Vice President, Global Head of Access Policy & Patient Advocacy, Oncology, Menarini Stemline
Mar 516:15
Conference pass

Enhancing collaborations with industry: improving patient ac-cess early in the development cycle

Rare Diseases, G105
Chantal van Litsenburg, Manager, Translational Effectiveness, Leiden University Medical Center (Netherlands)
Mar 516:15
Conference pass

Developing blockchain platforms for real world evidence generation in small population studies

Digital Transformation, G106
Mar 516:15
Conference pass

Cost effectiveness and early access arrangements

HTA, Exhibition Hall
Hans Severens, Independent HTA Expert, Severens HTA Consultancy
Mar 516:15
Conference pass

Societal perspectives in cost effectiveness analyses: a comprehensive assessment

Health Economics & Outcomes Research, G107
Matthias Bischof, Senior Director, International Health Economics, Novartis
Mar 516:35
Conference pass

Networking Break

Keynotes

Networking break in exhibition hall

Mar 517:20
Conference pass

Chair's Remarks

Real World Evidence & Data, G102

Chair's remarks

Mark Cawley, Associate Director, R&D Procurement, Jazz Pharmaceuticals
Mar 517:20
Conference pass

Chair's Remarks

Market Access, Auditorium
Michael Mueller, Head of Market Access, Western Europe, Sun Pharma
Mar 517:20
Conference pass

Chair's Remarks

Pricing, Exhibition Hall

Chair's Remarks

Simon Shohet, Vice President, International Market Access, Amicus Therapeutics
Mar 517:20
Conference pass

Chair's Remarks

Pre-Launch Success, G103
Mar 517:20
Conference pass

Chair's Remarks

Reimbursement, G104
Mar 517:20
Conference pass

Chair's Remarks

Rare Diseases, G105
Kaan Tunceli, Vice President and Head, Global Value and Real World Evidence, Otsuka Pharmaceutical
Mar 517:20
Conference pass

Chair's Remarks

Digital Transformation, G106

Chair's Remarks

Mar 517:20
Conference pass

Chair's Remarks

HTA, Exhibition Hall

Chair's Remarks

Eric Noehrenberg, Global Vice President, Market Access and Government Affairs, CORCYM
Mar 517:20
Conference pass

Chair's Remarks

Health Economics & Outcomes Research, G107

Chair's Remarks

Mar 517:25
Conference pass

Sponsor presentation

Real World Evidence & Data, G102

Reserved for sponsor

Mar 517:25
Conference pass

Net prices & award criteria – The key ingredients for optimal tender pricing

Market Access, Auditorium
Nico Bacharidis, Chief Commercial Officer, CUBE RM
Mar 517:25
Conference pass

Market access dynamics – a game theorist's perspective

Pricing, Exhibition Hall

Reserved for sponsor

Oliver Viehmann, Principal and Practice Group Leader Pharma & Life Sciences, TWS Partners
Louwrens Wendelaar Bonga, Commercial Development Director, Pfizer
Mar 517:25
Conference pass

Sponsor presentation

Pre-Launch Success, G103

Reserved for sponsor

Mar 517:25
Conference pass

Reimbursement, health equity, and sustainability for market access success

Reimbursement, G104
Mar 517:25
Conference pass

Sponsor presentation

Rare Diseases, G105

Reserved for sponsor

Andrea Parodi, Executive Vice President, Head of Biostatistics, Valos Srl
Mar 517:25
Conference pass

Reserved for Deloitte

Digital Transformation, G106

Reserved for Deloitte

Mar 517:25
Conference pass

Sponsor presentation

Digital Transformation, G106

Reserved for sponsor

Mar 517:25
Conference pass

Sponsor presentation

HTA, Exhibition Hall

Reserved for sponsor

Mar 517:25
Conference pass

Transformative solutions in healthcare: a total system value framework

Health Economics & Outcomes Research, G107

Reserved for sponsor

Phil McEwan, CEO, HEOR
Mar 517:45
Conference pass

Title TBC

Real World Evidence & Data, G102
Lianne Barnieh, Associate Director, HEOR, BeiGene
Mar 517:45
Conference pass

Early access programs: Italian experiences

Market Access, Auditorium
Silvia Miriam Cammarata, Senior Regulatory Affairs and Health Policy Specialist, AIFA Italian Medicine Agency
Mar 517:45
Conference pass

Challenges and opportunities for multi-indication pricing

Pricing, Exhibition Hall
Julien Patris, Head of Patient Advocacy, Public Policy, Corporate Communications, EMEA, arGEN-X
Mar 517:45
Conference pass

Elevating market access to enable successful launches

Pre-Launch Success, G103
Mar 517:45
Conference pass

Reimbursement and negotiating access to orphan medications: regulatory and policy hurdles

Reimbursement, G104
Mar 517:45
Conference pass

A global call to action for rare diseases

Rare Diseases, G105
Philippe Ghyssels, Vice President, Global Public Affairs, IPSEN
Jan Swiderski, Director, Head of Global Public Affairs and Advocacy, IPSEN
Mar 517:45
Conference pass

How AI will disrupt market access practice

Digital Transformation, G106
Mondher Toumi, Professor of Public Health, Aix-Marseille University
Mar 517:45
Conference pass

HTA of artificial intelligence: special considerations and development of a checklist

HTA, Exhibition Hall

Speaker presentation

Antonia Needham-Taylor, Health Services Researcher, Health Technology Wales
Mar 517:45
Conference pass

Challenges in conceptualizing a de-novo cost-effectiveness model for a rare disease.

Health Economics & Outcomes Research, G107

Speaker presentation

Martí Hopmans, Senior Global Market Access Manager, Ferrer International
Mar 518:05
Conference pass

Close of conference and drinks reception

Keynotes

Drink reception in exhibition hall

Create your personal agenda –check the favourite icon

Mar 68:55
Conference pass

Chair's Remarks

Keynotes

Keynote session

Charles Makin, Head of RWE, Boehringer Ingelheim
Mar 69:00
Conference pass

Pathways to overcoming access barriers in LMICs

Keynotes
Claus Runge, Chief Health Equity Officer, Senior Vice President, Global Head of Public Affairs, Sustainability & Int. Engagement, Bayer
Mar 69:20
Conference pass

How to plan for JCA adoption through managed entry agreements

Keynotes
Fredrik Eisner, Senior Director, Pricing & Market Access, Parexel
Mar 69:40
Conference pass

Environmental sustainability and access to medicines – the way forward

Keynotes
Elena Tricca, Vice President, Global Market Access and Pricing, BioPharmaceuticals, AstraZeneca
Mar 610:00
Conference pass

Keynote presentation - Valid Insight

Keynotes

Keynote presentation - Valid Insight

Mar 610:20
Conference pass

Keynote panel discussion: Global healthcare reforms and their implications on local market access strategy

Keynotes
Arup Pramanik, Corporate Vice President, Head of Global Market Access, TA Inflammation, Boehringer Ingelheim
Sandro Cesaro, Head of Europe Market Access & Pricing, AstraZeneca
Gavin Lewis, Senior Vice President, Head of Value and Access, Novartis
Moderator: Annette Powers, Senior Vice President, Global Market Access, Bristol Myers Squibb
Christina Hoxer, Vice President, Global Head of Diabetes Market Access, Novo Nordisk
Mar 611:55
Conference pass

Chair's Remarks

Real World Evidence & Data, G102
Madhu Kabra, Global Director, HEOR &RWE, MKGlobal
Mar 611:55
Conference pass

Chair's Remarks

Pricing, Exhibition Hall
Jiri Smejkal, Head of Pricing and Tender Excellence PDT, Takeda
Mar 611:55
Conference pass

Chair's Remarks

Pre-Launch Success, G103
Ana Filipa Alexandre, Senior Director, Pipeline Head for Neuroscience, Teva Pharmaceuticals
Mar 611:55
Conference pass
Mar 611:55
Conference pass

Chair's Remarks

Rare Diseases, G105
Marcus Droege, Senior Advisor, Market Access & Commercial, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Mar 611:55
Conference pass

Chair's Remarks

Digital Transformation, G106

Chair's Remarks

Mar 611:55
Conference pass
Mar 612:00
Conference pass

Value based approaches to searching, screening and developing RWD strategic partnerships

Real World Evidence & Data, G102
Mar 612:00
Conference pass

Opportunities for harmonisation of PROMs for market access

Market Access, Auditorium
Grace Jennings, Senior Director, Outcomes Research, ICHOM
Mar 612:00
Conference pass

Commercial market access excellence: assessing returns and successes of market access and pricing

Pricing, Exhibition Hall
Mar 612:00
Conference pass

Providing frameworks, incentives and tools to enable successful product development

Pre-Launch Success, G103
Mar 612:00
Conference pass

Innovative reimbursement schemes: uncertainties and performance indicators

Reimbursement, G104
Ad Antonisse, Director, Market Access & Corporate Affairs, AstraZeneca
Mar 612:00
Conference pass

Bringing in patient voices to health authorities and industry

Rare Diseases, G105
Sofiya Got, Strategy and Transformation Analyst, NHS
Mar 612:00
Conference pass

Developing new HTA frameworks and methodologies for digital health technologies: the EDiHTA project

Digital Transformation, G106
Emmanouil Tsiasiotis, Research Project Manager and Coordinator, EDiHTA
Wija Oortwijn, Chair of Appraisal Committee at ZINL & Assistant Professor, HTA, ZIN & Radboud University Medical Center
Mar 612:00
Conference pass

How the BEAMER Compass is improving patient support, outcomes and cost-effectiveness

Health Economics & Outcomes Research, G107

Non-adherence to treatment has major impact to the efficiency and cost of healthcare systems and our wider societies. The BEAMER COMPASS provides a pragmatic framework designed to understand patient needs and create actionable sub-groups, enabling the future design and delivery of effective and targeted patient support. This approach enhances treatment adherence and persistence across all disease areas. The framework relates to all the HEOR top 10 focus areas, from Health Equity and Patient-Centricity to Value and Pricing, providing a foundation for future development in precision medicine.

Mar 612:20
Conference pass

Achieving better evidence management and value communications with AI

Real World Evidence & Data, G102
David McConkey, Partner, Access Infinity
Mar 612:20
Conference pass

Rare but real: transforming challenges into opportunities for rare disease patients

Market Access, Auditorium
Mar 612:20
Conference pass

The key global drug pricing trends

Pricing, Exhibition Hall

Reserved for sponsor

Alan Crowther, General Manager, Global Pricing & Access, Eversana
Mar 612:20
Conference pass

Sponsor presentation

Pre-Launch Success, G103

Reserved for sponsor

Mar 612:20
Conference pass

The strategic role of real-world evidence in shaping EU HTA assessments for rare diseases

Reimbursement, G104

Reserved for sponsor

Nicole Tunstall, Vice President, International Market Access Consulting, GmbH
Mar 612:20
Conference pass

Drug-device combination products for orphan diseases: dealing with unmet needs and data uncertainty

Rare Diseases, G105

Reserved for sponsor

Lotta Parviainen, Head of Global Market Access, Zambon France
Mar 612:20
Conference pass

Sponsor presentation

Digital Transformation, G106

Reserved for Sponsor

Mar 612:20
Conference pass

Sponsor presentation

HTA, Exhibition Hall

Reserved for sponsor

Mar 612:20
Conference pass

Session Reserved for PharmacoEvidence

Health Economics & Outcomes Research, G107

Session Reserved for PharmacoEvidence

Mar 612:40
Conference pass

Digitizing the integrated evidence plan, benefits and learnings

Real World Evidence & Data, G102
Mar 612:40
Conference pass

Applicability and generalizability of US community oncology EHR data to support robust global evidence dossiers

Market Access, Auditorium
Mar 612:40
Conference pass

Implications of crossborder collaborations for pricing and procurement

Pricing, Exhibition Hall
Neil Grubert, Global Market Access Expert, Independent
Mar 612:40
Conference pass

Evidence generated from clinical trials to maximise reimbursement

Reimbursement, G104
Ankita Kaushik, Senior Director, HEOR, Global Value and Access, Gilead Sciences
Mar 612:40
Conference pass

Drug-device combination products for orphan diseases: dealing with unmet needs and data uncertainty

Rare Diseases, G105
Mar 612:40
Conference pass

Omni channel approaches to improve customer interactions through digital and other pathways

Digital Transformation, G106
Aodan Tynan, Vice President, Global Market Access, Astellas
Mar 612:40
Conference pass

Balancing cost-effectiveness and affordability: Developing methodological approaches to implement complex and high-volume products in the NHS

HTA, Exhibition Hall

Reserved for NICE

Helen Knight, Director of Medicines Evaluation, NICE
Mar 612:40
Conference pass

The value of investing in healthcare systems for the future

Health Economics & Outcomes Research, G107

Speaker presentation

Christina Vandorou, Director, Macroeconomics And Health Policy, EMEA, Johnson & Johnson Innovative Medicine
Mar 613:00
Conference pass

Sponsor presentation

Real World Evidence & Data, G102

Reserved for sponsor

Mar 613:00
Conference pass

Successful value retention through effective loss of exclusivity (LOE)

Market Access, Auditorium
Ruven Remo Eul, Principal and Chief Commercial Officer, Marbls
Raquel Santos, Manager, Marbls
Mar 613:00
Conference pass

Session Reserved for Stratence Partners

Pricing, Exhibition Hall

Session Reserved for Stratence Partners

Mar 613:00
Conference pass

Session Reserved for AMICULUM

Pre-Launch Success, G103

Reserved for sponsor

Mar 613:00
Conference pass

Sponsor presentation

Reimbursement, G104

Reserved for sponsor

Mar 613:00
Conference pass

Sponsor presentation

Rare Diseases, G105

Reserved for sponsor

Mar 613:00
Conference pass

Sponsor presentation

Digital Transformation, G106

Reserved for sponsor

Mar 613:00
Conference pass

Session Reserved for AESARA

HTA, Exhibition Hall

Reserved for AESARA

Mar 613:00
Conference pass

Sponsor presentation

Health Economics & Outcomes Research, G107

Reserved for sponsor

Mar 613:20
Conference pass

Lunch

Keynotes

Lunch in exhibition hall

Mar 614:45
Conference pass

01 Real World Evidence & Data Panel – From data to decisions: harnessing evidence for seamless product launches

Real World Evidence & Data, G102
Sylvie Greneche, Head of Global Market Access, General Medicines, Sanofi
Neeta Tandon, Vice President, Value & Evidence Scientific Engagement, Johnson & Johnson Innovation
Anupama Rao Singh, Group Country Head -LATAM | Head - Oncology and Hospital Business CoE, Emerging Markets, Dr. Reddy's Laboratories Ltd.
Sandra Rose, Head of Market Access & Public Affairs, Chiesi
Moderator: Paul Slobbe, Director, Market Access and External Affairs, Takeda Nederland
Mar 614:45
Conference pass

02 Market Access Panel – Improving access to gene therapies: challenges and key learnings

Market Access, Auditorium
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
Andrew Olaye, Head of EMEA Market Access, Orchard Therapeutics Ltd
Loic Gauthier, Global Pricing Director, CSL Behring
Moderator: Dilip Patel, SVP, Pricing, Value & Access Strategy, Autolus
Don Creighton, Executive Director, Market Access Pipeline and Readiness Lead, Regeneron
Mar 614:45
Conference pass

03 Pricing Panel – Value based healthcare in theory and practice: challenges for pricing

Pricing, Exhibition Hall
Emanuele Degortes, Vice President, Global Head of Access Policy and Patient Advocacy, Menarini
Igor Solev, Global Head, Market Access, Policy & External Payer Affairs, Abbott Laboratories
Chris Prins, Policy Advisor Expensive Medicines, Zorgverzekeraars Nederland
Moderator: Jose Aragunde, Value and Pricing Strategy Lead, Market Access, Novartis
Rhys Williams, Vice President, Evidence Generation Strategy and Health Economics, Global Medical Affairs (ex-China), BeiGene
Mar 614:45
Conference pass

04 Pre-launch Success Panel – Access Infinity

Pre-Launch Success, G103

Session Reserved for Access Infinity

Mar 614:45
Conference pass

04 Pre-launch Success Panel – Access Infinity

Pre-Launch Success, G103

Session Reserved for Access Infinity

Mar 614:45
Conference pass

05 Reimbursement Panel – Sustainability of healthcare: reimbursement driven by affordability constraints

Reimbursement, G104
Mary Lynne van Poelgeest-Pomfret, President, World Federation for Incontinence and Pelvic Problems (WFIPP)
Chiara Brouns, Strategic purchaser, Zorgverzekeraars Nederland
Daniel Jackson, Global Head, Payer Evidence Synthesis, UCB
Marie-Monique de Molliens, Global Market Access Horizon Scanning Senior Director, Sanofi
Marta Andreykiv, Head of Market Access Europe, Viatris
Mar 614:45
Conference pass

06 Rare Diseases Panel – Delivering pharmaceutical innovation across the globe: WHO Europe & the Novel Medicines Platform

Rare Diseases, G105
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics
Jean Christophe Goirand, Senior Director, Global Head Market Access & Pricing, Essential Pharma
Antonella Cardone, CEO, Cancer Patients Europe
Tomasz Kluszczynski, Strategy Consultant & Founder, ACESO Healthcare
Bettina Ryll, Founder, Melanoma Patient Network Europe, MPNE
Moderator: Thomas Grub, Director Global Pricing and Market Access, medac GmbH
Mar 614:45
Conference pass

07 Reimbursement Panel - Sustainable patient access through value-based reimbursement strategies

Digital Transformation, G106

Value-based healthcare is transforming patient access to innovation while helping payers navigate uncertainties related to clinical evidence gaps and rising costs that threaten system sustainability. However, its adoption in healthcare reimbursement remains uneven across markets and therapeutic areas due to concerns about complexity and administrative burden. This panel will bring together key stakeholders—including payers, industry leaders, providers, and patients—to explore both the opportunities and challenges of value-based healthcare. We will also examine potential solutions, such as digitalization, to streamline implementation and drive sustainable improvements.

Mar 614:45
Conference pass

08 HTA Panel – Rethinking added values of AI in HTA: debunking myths

HTA, Exhibition Hall
Dalia Dawoud, Associate Director, Research, NICE
Rishi Das-Gupta, Chief Executive Officer, Health Innovation Network
Oresta Piniazhko, Director, Hta Department, Ministry of Health, Ukraine
Alen Marijam, Senior Director, Vaccines, HEOR and Epidemiology Lead, Europe, Gsk
Mar 615:45
Conference pass

Chair's Remarks

Real World Evidence & Data, G102

Chair's Remarks

Marisca Marian, Oncology Market Access, Strategy Lead, Bayer
Mar 615:45
Conference pass

Chair's Remarks

Market Access, Auditorium

Chair's Remarks

Shane Elder, Head of Market Access, Europe & Canada, AstraZeneca
Mar 615:45
Conference pass

Chair's Remarks

Pricing, Exhibition Hall

Chair's Remarks

Gustavo Saraiva dos Anjos, Head of Pricing and Market Access Europe, Teva
Mar 615:45
Conference pass

Chair's Remarks

Pre-Launch Success, G103

Chair's Remarks

Sandra Margunato-Debay, Senior Director, Global Market Access, Genmab
Mar 615:45
Conference pass

Chair's Remarks

Reimbursement, G104

Chair's Remarks

Amit Kulkarni, Head of Health Economic Modeling and Decision Sciences, Otsuka
Mar 615:45
Conference pass
Mar 615:45
Conference pass

Chair's Remarks

Digital Transformation, G106

Chair's Remarks

Mar 615:45
Conference pass

Chair's Remarks

HTA, Exhibition Hall

Chair's Remarks

Mar 615:45
Conference pass

Chair's Remarks

Health Economics & Outcomes Research, G107

Chair's Remarks

Thomas Butt, Executive Director, Health Economics & Outcomes Research, Biomarin
Mar 615:50
Conference pass

Real-world evidence in Germany: challenges for industry

Real World Evidence & Data, G102

Speaker presentation

Mar 615:50
Conference pass

PICO and Market Access: How can we align objectives with timelines for success?

Market Access, Auditorium

Session reserved for IPSOS

Sabina Heinz, Senior Principal, Market Access Europe, Ipsos Market Access
Mar 615:50
Conference pass

Price negotiation evolution in Spain

Pricing, Exhibition Hall

Speaker presentation

José Luis Sánchez, Director, Market Access, Spain and Portugal, Jazz Pharmaceuticals
Mar 615:50
Conference pass

Incorporating early advice from HTA bodies and local levels to ensure successful international launches

Pre-Launch Success, G103
Tina Fischer, Head of Health Technology Assessments, Oncology, Daiichi-sankyo
Mar 615:50
Conference pass

Societal impact: NL case studies in HCV and CAR T

Reimbursement, G104

Speaker presentation

Henriette Burghoorn, Associate Director, Market Access, GIlead
Angela Borghouts - de Ruijter, Senior Pricing and Market Access Manager, Cell Therapy, Gilead Sciences
Mar 615:50
Conference pass

Challenges and opportunities to launching two assets in one rare disease indication

Rare Diseases, G105

Speaker presentation

Sebastian Kessel, Senior Director, Head of Market Access & Public Affairs, Germany, UCB
Mar 615:50
Conference pass

Speaker presentation

Digital Transformation, G106

Speaker presentation

Mar 615:50
Conference pass

Opportunities for harmonisation of PROMs for market access

HTA, Exhibition Hall

Speaker presentation

Grace Jennings, Senior Director, Outcomes Research, ICHOM
Mar 615:50
Conference pass

PICO prediction using an AI-enabled tool

Health Economics & Outcomes Research, G107

Speaker presentation

Silvy Mardiguian, Senior Director, Head of HEOR, Europe & New Markets, BeiGene
Mar 616:10
Conference pass

Sponsor presentation

Real World Evidence & Data, G102

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

Pricing, Exhibition Hall

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

Pre-Launch Success, G103

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

Reimbursement, G104

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

Rare Diseases, G105

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

Digital Transformation, G106

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

HTA, Exhibition Hall

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

Health Economics & Outcomes Research, G107

Reserved for sponsor

Mar 616:30
Conference pass

Session Reserved for ICHOM

Real World Evidence & Data, G102

Speaker presentation

Mar 616:30
Conference pass

Pricing implications and time horizon for cell and gene therapies: auto-immune diseases versus oncology

Pricing, Exhibition Hall

Speaker presentation

Peter Takacs, Head of Global Market Access, Miltenyi Biomedicine
Mar 616:30
Conference pass

Speaker presentation

Pre-Launch Success, G103

Speaker presentation

Mar 616:30
Conference pass

Assessing the highly specialised technologies programme at NICE: case studies in two treatments for ultra rare diseases

Rare Diseases, G105

Speaker presentation

Mar 616:30
Conference pass

Speaker presentation

Digital Transformation, G106

Speaker presentation

Mar 616:30
Conference pass

Speaker presentation

HTA, Exhibition Hall

Speaker presentation

Mar 616:30
Conference pass

Speaker presentation

Health Economics & Outcomes Research, G107

Speaker presentation

last published: 07/Feb/25 13:45 GMT
 
 

Get Involved 
 

Sponsorship & Exhibition Sales


David Boore 
david.boore@terrapinn.com
+44 20 8164 3052

Conference Production


George Mullens
george.mullens@terrapinn.com
+44 20 8164 3940

Marketing Opportunities


Karen Duncan
karen.duncan@terrapinn.com